These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 24861938)

  • 1. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics.
    Gorovits B; Peng K; Kromminga A
    BioDrugs; 2020 Feb; 34(1):39-54. PubMed ID: 31641991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.
    Kloks C; Berger C; Cortez P; Dean Y; Heinrich J; Bjerring Jensen L; Koppenburg V; Kostense S; Kramer D; Spindeldreher S; Kirby H
    J Immunol Methods; 2015 Feb; 417():1-9. PubMed ID: 25602137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.
    Tatarewicz SM; Mytych DT; Manning MS; Swanson SJ; Moxness MS; Chirmule N
    Bioanalysis; 2014 Jun; 6(11):1509-23. PubMed ID: 25046051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics.
    Wu B; Chung S; Jiang XR; McNally J; Pedras-Vasconcelos J; Pillutla R; White JT; Xu Y; Gupta S
    AAPS J; 2016 Nov; 18(6):1335-1350. PubMed ID: 27495119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk.
    Bivi N; Moore T; Rodgers G; Denning H; Shockley T; Swearingen CA; Gelfanova V; Calderon B; Peterson DA; Hodsdon ME; Siegel RW; Higgs RE; Konrad RJ
    MAbs; 2019 Jul; 11(5):861-869. PubMed ID: 31099718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.
    Gupta S; Devanarayan V; Finco D; Gunn GR; Kirshner S; Richards S; Rup B; Song A; Subramanyam M
    J Pharm Biomed Anal; 2011 Jul; 55(5):878-88. PubMed ID: 21531522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).
    Liao K; Sikkema D; Wang C; Lee TN
    J Immunol Methods; 2013 Mar; 389(1-2):52-60. PubMed ID: 23298658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics.
    Kropshofer H; Singer T
    J Immunotoxicol; 2006 Sep; 3(3):131-6. PubMed ID: 18958693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
    Xu W; Jiang H; Titsch C; Haulenbeek JR; Pillutla RC; Aubry AF; DeSilva BS; Arnold ME; Zeng J; Dodge RW
    J Immunol Methods; 2015 Jan; 416():94-104. PubMed ID: 25445325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials.
    Carrasco-Triguero M; Dere RC; Milojic-Blair M; Saad OM; Nazzal D; Hong K; Kaur S
    Bioanalysis; 2019 Sep; 11(17):1555-1568. PubMed ID: 31208199
    [No Abstract]   [Full Text] [Related]  

  • 16. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.
    Koren E; Smith HW; Shores E; Shankar G; Finco-Kent D; Rup B; Barrett YC; Devanarayan V; Gorovits B; Gupta S; Parish T; Quarmby V; Moxness M; Swanson SJ; Taniguchi G; Zuckerman LA; Stebbins CC; Mire-Sluis A
    J Immunol Methods; 2008 Apr; 333(1-2):1-9. PubMed ID: 18275969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cell-based and non-cell-based assay platforms for the detection of clinically relevant anti-drug neutralizing antibodies for immunogenicity assessment of therapeutic proteins.
    Hu J; Wala I; Han H; Nagatani J; Barger T; Civoli F; Kaliyaperumal A; Zhuang Y; Gupta S
    J Immunol Methods; 2015 Apr; 419():1-8. PubMed ID: 25795420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Cell-Based Assay for the Detection of Neutralizing Antibodies to PF-06730512 Using Homogenous Time-Resolved Fluorescence.
    Luong M; Wang Y; Berasi SP; Buhlmann JE; Yang H; Gorovits B
    AAPS J; 2020 Mar; 22(2):56. PubMed ID: 32166588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.